Meditor Group Ltd

disclosed that they own a 8.2% stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, August 21st. The investor owns 2,103,200 shares of the stock worth $94,097,168. The disclosure is available through the SEC website at this hyperlink.

Meditor Group Ltd

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
2,103,200
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Other large investors also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $205,000. Tower Research Capital LLC TRC increased its stake in shares of Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 4,856 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. 85.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics, Inc. (NASDAQ ESPR) traded down 2.08% during midday trading on Monday, hitting $43.81. The stock had a trading volume of 414,434 shares. The firm has a 50-day moving average price of $47.33 and a 200-day moving average price of $36.54. The firm’s market capitalization is $989.80 million. Esperion Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by $0.25. During the same period in the previous year, the firm posted ($0.62) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post ($7.39) earnings per share for the current year.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/esperion-therapeutics-inc-espr-stake-held-by-meditor-group-ltd/1513879.html.

A number of analysts have commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $85.00 target price on shares of Esperion Therapeutics in a report on Monday. Bank of America Corporation reiterated a “neutral” rating and issued a $60.00 target price on shares of Esperion Therapeutics in a report on Friday, August 11th. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 target price (up previously from $60.00) on shares of Esperion Therapeutics in a report on Thursday, August 10th. Finally, Deutsche Bank AG set a $64.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $44.65.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.